Verona Pharma (VRNA) News Today $42.25 +0.59 (+1.42%) (As of 09:51 AM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Verona Pharma plc (NASDAQ:VRNA) Given Consensus Rating of "Buy" by AnalystsVerona Pharma plc (NASDAQ:VRNA - Get Free Report) has been assigned a consensus rating of "Buy" from the six research firms that are covering the stock, MarketBeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among analysts that hDecember 17 at 2:21 AM | marketbeat.comVerona Pharma (NASDAQ:VRNA) Hits New 52-Week High - What's Next?Verona Pharma (NASDAQ:VRNA) Hits New 12-Month High - Here's WhyDecember 16 at 2:53 PM | marketbeat.comWellington Management Group LLP Buys 307,272 Shares of Verona Pharma plc (NASDAQ:VRNA)Wellington Management Group LLP raised its stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 19.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,878,632 shares of the company's stock after acquiring an additional 307,27December 12, 2024 | marketbeat.comVerition Fund Management LLC Acquires New Position in Verona Pharma plc (NASDAQ:VRNA)Verition Fund Management LLC bought a new position in Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 17,170 shares of the company's stock, valued at approximately $494,000. OtherDecember 12, 2024 | marketbeat.comVerona Pharma (VRNA) Gets a Buy from Truist FinancialDecember 11, 2024 | markets.businessinsider.comFrazier Life Sciences Management L.P. Grows Stake in Verona Pharma plc (NASDAQ:VRNA)Frazier Life Sciences Management L.P. lifted its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 2.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,383,950 shares of the company's stock after purDecember 10, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $920,477.28 in StockDecember 9, 2024 | americanbankingnews.comDorsey Wright & Associates Invests $2.31 Million in Verona Pharma plc (NASDAQ:VRNA)Dorsey Wright & Associates purchased a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 80,194 shares of the company's stock, valued aDecember 8, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 38,434 Shares of Verona Pharma plc (NASDAQ:VRNA)BNP Paribas Financial Markets raised its holdings in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 176.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 60,211 shares of the company's stock after buying an additional 38,434 shares duDecember 8, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Purchased by The Manufacturers Life Insurance CompanyThe Manufacturers Life Insurance Company increased its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 77.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 105,159 shares of the company'sDecember 8, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Sells $290,920.00 in StockDecember 7, 2024 | insidertrades.comJanus Henderson Group PLC Sells 49,247 Shares of Verona Pharma plc (NASDAQ:VRNA)Janus Henderson Group PLC trimmed its holdings in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 4.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,042,795 shares of the company's stock afterDecember 7, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 58,184 SharesVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 58,184 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $5.00, for a total value of $290,920.00. Following the completion of the transaction, the chief financial officer now directly owns 14,117,512 shares of the company's stock, valued at approximately $70,587,560. The trade was a 0.41 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.December 6, 2024 | marketbeat.comDavid Zaccardelli Sells 67,608 Shares of Verona Pharma plc (NASDAQ:VRNA) StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 67,608 shares of the company's stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $5.00, for a total value of $338,040.00. Following the transaction, the chief executive officer now directly owns 15,007,816 shares in the company, valued at approximately $75,039,080. The trade was a 0.45 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.December 6, 2024 | marketbeat.comDavid Zaccardelli Sells 162,800 Shares of Verona Pharma plc (NASDAQ:VRNA) StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CEO David Zaccardelli sold 162,800 shares of the firm's stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $5.01, for a total transaction of $815,628.00. Following the sale, the chief executive officer now directly owns 14,204,752 shares of the company's stock, valued at $71,165,807.52. This trade represents a 1.13 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.December 6, 2024 | marketbeat.comInsider Selling: Verona Pharma plc (NASDAQ:VRNA) CFO Sells 183,728 Shares of StockVerona Pharma plc (NASDAQ:VRNA - Get Free Report) CFO Mark W. Hahn sold 183,728 shares of Verona Pharma stock in a transaction on Friday, December 6th. The shares were sold at an average price of $5.01, for a total transaction of $920,477.28. Following the completion of the transaction, the chief financial officer now owns 13,293,736 shares in the company, valued at approximately $66,601,617.36. This trade represents a 1.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.December 6, 2024 | marketbeat.comSamsara BioCapital LLC Sells 152,275 Shares of Verona Pharma plc (NASDAQ:VRNA)Samsara BioCapital LLC lowered its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 43.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 195,225 shares of the company's stock after selling 152,275 shaDecember 5, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Stock Position Reduced by RA Capital Management L.P.RA Capital Management L.P. decreased its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 34.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,009,653 shares of the company's stock after selling 2December 5, 2024 | marketbeat.com64,605 Shares in Verona Pharma plc (NASDAQ:VRNA) Purchased by Walleye Capital LLCWalleye Capital LLC bought a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 64,605 shares of the company's stock, valDecember 5, 2024 | marketbeat.comTownsquare Capital LLC Invests $507,000 in Verona Pharma plc (NASDAQ:VRNA)Townsquare Capital LLC bought a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,626 shares of the company's stock, valued at appDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Has $18.02 Million Stake in Verona Pharma plc (NASDAQ:VRNA)Parkman Healthcare Partners LLC raised its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 5.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 626,452 shares of the company's stock after acquiring an additional 31,063 shares dDecember 4, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 3,200 SharesDecember 3, 2024 | insidertrades.comJefferies Sticks to Their Buy Rating for Verona Pharma (VRNA)December 2, 2024 | markets.businessinsider.comVerona Pharma plc (NASDAQ:VRNA) Shares Bought by Bellevue Group AGBellevue Group AG grew its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 7.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,220,059 shares of the company's stock after purchasing an aDecember 1, 2024 | marketbeat.comCaligan Partners LP Has $41.34 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)Caligan Partners LP decreased its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 22.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,436,878 shares of the company's stock after sellinDecember 1, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Short Interest Down 20.5% in NovemberVerona Pharma plc (NASDAQ:VRNA - Get Free Report) was the target of a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 5,980,000 shares, a decline of 20.5% from the October 31st total of 7,520,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is currently 5.8 days.November 30, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Reaches New 52-Week High - Time to Buy?Verona Pharma (NASDAQ:VRNA) Reaches New 52-Week High - Should You Buy?November 29, 2024 | marketbeat.comEventide Asset Management LLC Raises Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)Eventide Asset Management LLC increased its position in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 359.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,425,846 shares of the company's stock aNovember 29, 2024 | marketbeat.comVerona Pharma: In COPD, There's A Corner With Their Name On ItNovember 27, 2024 | seekingalpha.comInsider Selling: Verona Pharma plc (NASDAQ:VRNA) Insider Sells 240,000 Shares of StockNovember 27, 2024 | insidertrades.comLoomis Sayles & Co. L P Acquires New Holdings in Verona Pharma plc (NASDAQ:VRNA)Loomis Sayles & Co. L P bought a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 1,111,096 shares of the company's stock, valued at approximately $31,966,000. Loomis Sayles & Co. L P ownedNovember 26, 2024 | marketbeat.comJennison Associates LLC Has $50.09 Million Stake in Verona Pharma plc (NASDAQ:VRNA)Jennison Associates LLC increased its stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) by 54.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,740,886 shares of the company's stock after purchasing an addiNovember 22, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Receives Consensus Rating of "Buy" from AnalystsVerona Pharma plc (NASDAQ:VRNA - Get Free Report) has earned a consensus recommendation of "Buy" from the six research firms that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that hNovember 22, 2024 | marketbeat.comAtria Investments Inc Acquires Shares of 19,054 Verona Pharma plc (NASDAQ:VRNA)Atria Investments Inc acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 19,054 shares of the company's stock, valued at approximately $November 20, 2024 | marketbeat.comVerona Pharma (NASDAQ:VRNA) Stock Price Up 3.4% - Still a Buy?Verona Pharma (NASDAQ:VRNA) Stock Price Up 3.4% - Here's WhyNovember 19, 2024 | marketbeat.com572,928 Shares in Verona Pharma plc (NASDAQ:VRNA) Bought by First Turn Management LLCFirst Turn Management LLC acquired a new position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 572,928 shares of the company's stock, valued at approximately $16,483,000. VNovember 19, 2024 | marketbeat.comVerona Pharma Announces December 2024 Investor Conference ParticipationNovember 19, 2024 | globenewswire.com29,513 Shares in Verona Pharma plc (NASDAQ:VRNA) Acquired by GSA Capital Partners LLPGSA Capital Partners LLP purchased a new stake in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 29,513 shares of the company's stock, valued at approximaNovember 17, 2024 | marketbeat.com16,150 Shares in Verona Pharma plc (NASDAQ:VRNA) Purchased by Crossmark Global Holdings Inc.Crossmark Global Holdings Inc. acquired a new stake in Verona Pharma plc (NASDAQ:VRNA - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,150 shares of the company's stock, valuedNovember 17, 2024 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) CEO David Zaccardelli Sells 2,400 SharesNovember 14, 2024 | insidertrades.comTruist Financial Issues a Buy Rating on Verona Pharma (VRNA)November 13, 2024 | markets.businessinsider.comVerona Pharma (NASDAQ:VRNA) Reaches New 52-Week High - Here's What HappenedVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High - Time to Buy?November 11, 2024 | marketbeat.comCaligan picks up a stake in Verona Pharma, seeing an opportunity to generate more valueNovember 9, 2024 | cnbc.comDavid R. Ebsworth Acquires 39,360 Shares of Verona Pharma plc (NASDAQ:VRNA) StockNovember 8, 2024 | insidertrades.comVerona Pharma management to meet with BTIGNovember 7, 2024 | markets.businessinsider.comBrokers Issue Forecasts for Verona Pharma FY2024 EarningsVerona Pharma plc (NASDAQ:VRNA - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Verona Pharma in a report released on Tuesday, November 5th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($2.16) per share forNovember 7, 2024 | marketbeat.comRosalind Advisors Inc. Increases Position in Verona Pharma plc (NASDAQ:VRNA)Rosalind Advisors Inc. raised its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 10.0% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 275,000 shares of the company's stock after acquiring aNovember 6, 2024 | marketbeat.comDavid Zaccardelli Sells 46,888 Shares of Verona Pharma plc (NASDAQ:VRNA) StockNovember 6, 2024 | insidertrades.comLife science firm's $76M expansion to boost volume at Wisconsin plantsNovember 5, 2024 | bizjournals.comRaleigh pharma's stock hits record high amid drug launchNovember 5, 2024 | bizjournals.com Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address How to piss off your liberal friends… and profit from it (Ad)Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies. To get the full details on the fake “energy crisis” of America, watch this now VRNA Media Mentions By Week VRNA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRNA News Sentiment▼1.060.65▲Average Medical News Sentiment VRNA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRNA Articles This Week▼54▲VRNA Articles Average Week Get Verona Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VRNA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News GMAB News RDY News SRPT News CTLT News PCVX News QGEN News ITCI News ROIV News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRNA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verona Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Verona Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VRNA Stock Alerts